The role of cannabinoid receptors in the descending modulation of pain

Pharmaceuticals

Volumn 3, Issue 8, 2010, Pages 2661-2673

  Palazzo, Enza ^a   Luongo, Livio ^a   de Novellis, Vito ^a   Rossi, Francesco ^a   Maione, Sabatino ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Antinociceptive descending pathway; Periaqueductal grey; Rostral ventromedial medulla

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 4 AMINOBUTYRIC ACID; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; ANANDAMIDE; ARACHIDONOYLSEROTONIN; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; DEXANABINOL; ENDOCANNABINOID; ENZYME INHIBITOR; FATTY ACID AMIDASE; RIMONABANT; TETRAHYDROCANNABINOLIC ACID; UNCLASSIFIED DRUG; VANILLOID RECEPTOR 1;

ANTINOCICEPTION; ARTICLE; DOSE RESPONSE; DRUG ANTAGONISM; GABAERGIC TRANSMISSION; HUMAN; LOW DRUG DOSE; NERVE STIMULATION; NERVE TRACT; NEUROMODULATION; NEUROPATHIC PAIN; NONHUMAN; PAIN; PAIN RECEPTOR; PROCESS DEVELOPMENT; PROTEIN EXPRESSION; PROTEIN FUNCTION; SENSITIVITY ANALYSIS; SIGNAL PROCESSING; SPINAL CORD DORSAL HORN; SPINAL PAIN;

EID: 77957268985     PISSN: None     EISSN: 14248247     Source Type: Journal    
DOI: 10.3390/ph3082661     Document Type: Article

References (82)

1. Iversen, L.; Chapman, V. Cannabinoids: a real prospect for pain relief? Curr. Opin. Pharmacol. 2002, 2, 50-55.
2. Pertwee, R.G. Cannabinoid receptors and pain. Prog. Neurobiol. 2001, 63, 569-611.
3. Maione, S.; Starowicz, K.; Palazzo, E.; Rossi, F.; Di Marzo, V. The endocannabinoid and endovanilloid systems and their interactions in neuropathic pain. Drug Dev. Res. 2006, 67, 1-16.
4. Rinaldi-Carmona, M.; Barth, F.; Heaulme, M.; Shire, D.; Calandra, B.; Congy, C.; Martinez, S.; Maruani, J.; Neliat, G.; Caput, D.; et al. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. 1994, 350, 240-244.
5. Hanus, L.; Breuer, A.; Tchilibon, S.; Shiloah, S.; Goldenberg, D.; Horowitz, M.; Pertwee, R.G.; Ross, R.A.; Mechoulam, R.; Fride, E. HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor. Proc. Natl. Acad. Sci. USA 1999, 96, 14228-14233.
6. Zimmer, A.; Zimmer, A.M.; Hohmann, A.G.; Herkenham, M.; Bonner, T.I. Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc. Natl. Acad. Sci. USA 1999, 96, 5780-5785.
7. Ledent, C.; Valverde, O.; Cossu, C.; Petitet, F.; Aubert, L.F.; Beslot, F.; Bohme, G.A.; Imperato, A.; Pedrazzini, T.; Roques, B.P.; et al. Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science 1999, 283, 401.
8. Svízenská, I.; Dubový, P.; Sulcová, A. Cannabinoid receptors 1 and 2 (CB1 and CB2), their distribution, ligands and functional involvement in nervous system structures--a short review. Pharmacol. Biochem. Behav. 2008, 90, 501-511.
9. Beltramo, M.; Bernardini, N.; Bertorelli, R.; Campanella, M.; Nicolussi, E.; Fredduzzi, S.; Reggiani, A. CB2 receptor-mediated antihyperalgesia: possible direct involvement of neural mechanisms. Eur. J. Neurosci. 2006, 23, 1530-1538.
10. Gong, J.P.; Onaivi, E.S.; Ishiguro, H.; Liu, Q.R.; Tagliaferro, P.A.; Brusco, A.; Uhl, G.R. Cannabinoid CB2 receptors: immunohistochemical localization in rat brain. Brain Res. 2006, 1071, 10-23.
11. van Sickle, M.D.; Duncan, M.; Kingsley, P.J.; Mouihate, A.; Urbani, P.; Mackie, K.; Stella, N.; Makriyannis, A; Piomelli, D.; Davison, J.S.; et al. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 2005, 310, 329-332.
12. Chin, C.L.; Tovcimak, A.E.; Hradil, V.P.; Seifert, T.R.; Hollingsworth, P.R.; Chandran, P.; Zhu, C.Z.; Gauvin, D.; Pai, M.; Wetter, J.; et al. Differential effects of cannabinoid receptor agonists on regional brain activity using pharmacological MRI. Br. J. Pharmacol. 2008, 153, 367-379.
13. Hohmann, A.G.; Tsou, K.; Walker, J.M. Cannabinoid modulation of wide dynamic range neurons in the lumbar dorsal horn of the rat by spinally administered WIN55,212-2. Neurosci. Lett. 1998, 257, 119-122.
14. Kelly, S.; Chapman, V. Selective cannabinoid CB1 receptor activation inhibits spinal nociceptive transmission in vivo. J. Neurophysiol. 2001, 86, 3061-3064.
15. Kelly, S.; Chapman, V. Cannabinoid CB(1) receptor inhibition of mechanically evoked responses of spinal neurones in control rats, but not in rats with hindpaw inflammation. Eur. J. Pharmacol. 2003, 474, 209-216.
16. Lichtman A.H.; Martin, B.R. Spinal and Supraspinal components of cannabinoid-induced antinociception. J. Pharmacol. Exp. Ther.1991, 258, 517-523.
17. Lichtman A.H.; Martin, B.R. Cannabinoid-induced antinociception is mediated by a spinal 2-noradrenergic mechanism. Brain Res. 1991, 559, 309-314.
18. Richardson, J.D.; Aanonsen, L.; Hargreaves, K.M. Antihyperalgesic effects of spinal cannabinoids. Eur. J. Pharmacol. 1998, 345, 145-153.
19. Agarwal, N.; Pacher, P.; Tegeder, I.; Amaya, F.; Constantin, C.E.; Brenner, G.J.; Rubino, T.; Michalski, C.W.; Marsicano, G.; Monory, K.; et al. Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors. Nat. Neurosci. 2007, 10, 870-879.
20. Zygmunt, P.M.; Petersson, J.; Andersson, D.A.; Chuang, H.; Sørgård, M.; Di Marzo, V.; Julius, D.; Högestätt, E.D. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 1999, 400, 452-457.
21. Pacher, P.; Bátkai, S.; Kunos, G. Haemodynamic profile and responsiveness to anandamide of TRPV1 receptor knock-out mice. J. Physiol. 2004, 558: 647-657.
22. Starowicz, K.; Nigam, S.; Di Marzo, V. Biochemistry and pharmacology of endovanilloids. Pharmacol. Ther. 2007, 114, 13-33.
23. Potenzieri, C.; Brink, T.S.; Simone, D.A. Excitation of cutaneous C nociceptors by intraplantar administration of anandamide. Brain Res. 2009, 1268, 38-47.
24. Singh Tahim, A.; Sántha, P.; Nagy, I. Inflammatory mediators convert anandamide into a potent activator of the vanilloid type 1 transient receptor potential receptor in nociceptive primary sensory neurons. Neuroscience 2005, 136, 539-548.
25. Watanabe, H.; Vriens, J.; Prenen, J.; Droogmans, G.; Voets, T.; Nilius, B. Anandamide and arachidonic acid use epoxyeicosatrienoic acids to activate TRPV4 channels. Nature 2003, 424, 434-438.
26. Vriens, J.; Owsianik, G.; Fisslthaler, B.; Suzuki, M.; Janssens, A.; Voets, T.; Morisseau, C.; Hammock, B.D.; Fleming, I.; Busse, R.; et al. Modulation of the Ca2 permeable cation channel TRPV4 by cytochrome P450 epoxygenases in vascular endothelium. Circ. Res. 2005, 97, 908-915.
27. Grant, A.D.; Cottrell, G.S.; Amadesi, S.; Trevisani, M.; Nicoletti, P.; Materazzi, S.; Altier, C.; Cenac, N.; Zamponi, G.W.; Bautista-Cruz, F.; et al. Protease-activated receptor 2 sensitizes the transient receptor potential vanilloid 4 ion channel to cause mechanical hyperalgesia in mice. J. Physiol. 2007, 578, 715-733.
28. Todaka, H.; Taniguchi, J.; Satoh, J.; Mizuno, A.; Suzuki, M. Warm temperature-sensitive transient receptor potential vanilloid 4 (TRPV4) plays an essential role in thermal hyperalgesia. J. Biol. Chem. 2004, 279, 35133-35138.
29. Akopian, A.N.; Ruparel, N.B.; Jeske, N.A.; Patwardhan, A.; Hargreaves, K.M. Role of ionotropic cannabinoid receptors in peripheral antinociception and antihyperalgesia. Trends Pharmacol. Sci. 2009, 30, 79-84.
30. Jordt, S.E.; Bautista, D.M.; Chuang H.H.; McKemy, D.D.; Zygmunt, P.M.; Högestätt E.D.; Meng, I.D.; Julius, D. Mustard oils and cannabinoids excite sensory nerve fibres through the TRP channel ANKTM1. Nature 2004, 427, 260-265
31. Hohmann, A.G.; Tsou, K.; Walker, J.M. Cannabinoid suppression of noxious heat-evoked activity in wide dynamic range neurons in the lumbar dorsal horn of the rat. J. Neurophysiol. 1999, 81, 575-583.
32. Martin, W.J.; Lai, N.K.; Patrick, S.L.; Tsou, K.; Walker, J.M. Antinociceptive actions of cannabinoids following intraventricular administration in rats. Brain Res. 1993, 629, 300-304.
33. Lichtman, A.H.; Cook, S.A.; Martin, B.R. Investigation of brain sites mediating cannabinoidinduced antinociception in rats: evidence supporting periaqueductal gray involvement. J. Pharmacol. Exp. Ther. 1996, 276, 585-593.
34. Martin, W.J.; Coffin, P.O.; Attias, E.; Balinsky, M.; Tsou, K.; Walker, J.M. Anatomical basis for cannabinoid-induced antinociception as revealed by intracerebral microinjections. Brain Res. 1999, 822, 237-242.
35. Martin, W.J.; Patrick, S.L.; Coffin, P.O.; Tsou, K.; Walker JM. An examination of the central sites of action of cannabinoid-induced antinociception in the rat. Life Sci. 1995, 56, 2103-2210.
36. Martin, W.J.; Tsou, K.; Walker, J.M. Cannabinoid receptor-mediated inhibition of the rat tail-fl ick reflex after microinjection into the rostral ventromedial medulla. Neurosci. Lett. 1998, 242, 33-36.
37. Finn, D.P.; Jhaveri, M.D.; Beckett, S.R.; Roe, C.H.; Kendall, D.A.; Marsden, C.A.; Chapman, V. Effects of direct periaqueductal grey administration of a cannabinoid receptor agonist on nociceptive and aversive responses in rats. Neuropharmacology 2003, 45, 594-604.
38. Reynolds, D.V. Surgery in the rat during electrical analgesia induced by focal brain stimulation. Science 1969, 164, 444-445.
39. Herkenham, M.; Lynn, A.B.; Johnson M.R.; Melvin, L.S.; de Costa, B.R.; Rice, K.C. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J. Neurosci. 1991, 11, 563-583.
40. Matsuda, L.A.; Bonner, T.I.; Lolait, S.J. Localization of cannabinoid receptor mRNA in rat brain. J. Comp. Neurol. 1993, 327, 535-550.
41. Tsou, K.; Brown, S.; Sañudo-Peña, M.C.; Mackie, K.; Walker, J.M. Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience 1998, 83, 393-411.
42. Meng, I.D.; Manning, B.H.; Martin, W.J.; Fields, H.L. An analgesia circuit activated by cannabinoids. Nature 1998, 395, 381-383.
43. Siegling, A.; Hofmann, H.A.; Denzer, D.; Mauler, F.; De Vry, J. Cannabinoid CB(1) receptor upregulation in a rat model of chronic neuropathic pain. Eur. J. Pharmacol. 2001, 415, R5-R7.
44. Zhang, J.; Hoffert, C.; Vu, H.K.; Groblewski, T.; Ahmad, S.; O'Donnell, D. Induction of CB2 receptor expression in the rat spinal cord of neuropathic but not inflammatory chronic pain models. Eur. J. Neurosci. 17, 2750-2754.
45. Pertwee, R.G. Inverse agonism and neutral antagonism at cannabinoid CB1 receptors. Life Sci. 2005, 76, 1307-1324.
46. Ross, R.A.; Brockie, H.C.; Stevenson, L.A.; Murphy, V.L.; Templeton, F.; Makriyannis, A.; Pertwee, R.G. Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656, and AM630. Br. J. Pharmacol. 1999, 126, 665-672.
47. Ryberg, E.; Larsson, N.; Sjögren, S.; Hjorth, S.; Hermansson, N.O.; Leonova, J.; Elebring, T.; Nilsson, K.; Drmota, T.; Greasley, P.J. The orphan receptor GPR55 is a novel cannabinoid receptor. Br. J. Pharmacol. 2007, 152, 1092-1101.
48. Mackie, K. Signaling via CNS cannabinoid receptors. Mol. Cell Endocrinol. 2008, 286, S60-S65.
49. Palazzo, E.; Marabese, I; de Novellis, V.; Oliva, P.; Rossi, F.; Berrino, L.; Rossi, F.; Maione, S. Metabotropic and NMDA glutamate receptors participate in the cannabinoid-induced antinociception. Neuropharmacology 2001, 40, 319-326.
50. Vaughan, C.W.; McGregor, I.S.; Christie, M.J. Cannabinoid receptor activation inhibits GABAergic neurotransmission in rostral ventromedial medulla neurons in vitro. Br. J. Pharmacol. 1999, 127, 935-940.
51. Vaughan, C.W.; Connor, M.; Bagley, E.E.; Christie, M.J. Actions of cannabinoids on membrane properties and synaptic transmission in rat periaqueductal gray neurons in vitro. Mol. Pharmacol. 2000, 57, 288-295.
52. Fields, H.L; Basbaum, A.I.; Heinricher, M.M. Central Nervous Systems Mechanisms of Pain Modulation. In Textbook of Pain, fifth ed.; McMahon S.B., Koltzenburg M., Eds.; Elsevier, Churchill Livingston: Philadelphia, PA, USA, 2006; pp. 125-142.
53. de Novellis, V.; Mariani, L.; Palazzo, E.; Vita, D.; Marabese, I.; Scafuro, M.; Rossi, F.; Maione S. Periaqueductal grey CB1 cannabinoid and metabotropic glutamate subtype 5 receptors modulate changes in rostral ventromedial medulla neuronal activities induced by subcutaneous formalin in the rat. Neuroscience 2005, 134, 269-281.
54. Fields, H.L.; Bry, J.; Hentall, I.; Zorman, G. The activity of neurons in rostral medulla of the rat during withdrawal from noxious heat. J. Neurosci. 1983, 3, 2545-2552.
55. Drew, G.M.; Mitchell, V.A.; Vaughan, C.W. Glutamate spillover modulates GABAergic synaptic transmission in the rat midbrain periaqueductal grey via metabotropic glutamate receptors and endocannabinoid signaling. J. Neurosci. 2008, 28, 808-815.
56. Drew, G.M.; Lau, B.K.; Vaughan, C.W. Substance P drives endocannabinoid-mediated disinhibition in a midbrain descending analgesic pathway. J. Neurosci. 2009, 29, 7220-7229.
57. Bisogno, T.; Howell, F.; Williams, G.; Minassi, A.; Cascio, M.G.; Ligresti, A.; Matias, I.; Schiano-Moriello, A.; Paul, P.; Williams, E.J.; et al. Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain. J. Cell Biol. 2003, 163, 463-468.
58. Hashimotodani, Y.; Ohno-Shosaku, T.; Tsubokawa, H.; Ogata, H.; Emoto, K.; Maejima, T.; Araishi, K.; Shin, H.S.; Kano, M. Phospholipase Cbeta serves as a coincidence detector through its Ca2+ dependency for triggering retrograde endocannabinoid signal. Neuron 2005, 45, 257-68.
59. Stella, N.; Schweitzer, P.; Piomelli, D. A second endogenous cannabinoid that modulates longterm potentiation. Nature 1997, 388, 773-778.
60. Freund, T.F.; Katona, I.; Piomelli, D. Role of endogenous cannabinoids in synaptic signaling. Physiol. Rev. 2003, 83, 1017-1066.
61. Chevaleyre, V.; Takahashi, K.A.; Castillo, P.E. Endocannabinoid-mediated synaptic plasticity in the CNS. Annu. Rev. Neurosci. 2006, 29, 37-76.
62. Gerdeman, G.L.; Ronesi, J.; Lovinger, D.M. Postsynaptic endocannabinoid release is critical to long-term depression in the striatum. Nat. Neurosci. 2002, 5, 446-451.
63. Varma, N.; Carlson, G.C.; Ledent, C.; Alger, B.E. Metabotropic glutamate receptors drive the endocannabinoid system in hippocampus. J. Neurosci. 2001, 21, RC188.
64. Ohno-Shosaku, T.; Tsubokawa, H.; Mizushima, I.; Yoneda, N.; Zimmer, A.; Kano, M. Presynaptic cannabinoid sensitivity is a major determinant of depolarization-induced retrograde suppression at hippocampal synapses. J. Neurosci. 2002, 22, 3864-3872.
65. Robbe, D.; Kopf, M.; Remaury, A.; Bockaert, J.; Manzoni, O.J. Endogenous cannabinoids mediate long-term synaptic depression in the nucleus accumbens. Proc. Natl. Acad. Sci. USA 2002, 99, 8384-8388.
66. Brown S.P., Brenowitz S.D., Regehr W.G. Brief presynaptic bursts evoke synapse-specific retrograde inhibition mediated by endogenous cannabinoids. Nat. Neurosci. 2003, 6, 1048-1057.
67. Chevaleyre, V.; Castillo, P.E. Heterosynaptic LTD of hippocampal GABAergic synapses: a novel role of endocannabinoids in regulating excitability. Neuron 2003, 38, 461-472.
68. Rouach, N.; Nicoll, R.A. Endocannabinoids contribute to short-term but not long-term mGluRinduced depression in the hippocampus. Eur. J. Neurosci. 2003, 18, 1017-1020.
69. Marsicano, G.; Wotjak, C.T.; Azad, S.C.; Bisogno, T.; Rammes, G.; Cascio, M.G.; Hermann, H.; Tang, J.; Hofmann, C.; Zieglgänsberger, W.; et al. The endogenous cannabinoid system controls extinction of aversive memories. Nature 2002, 418, 530-534.
70. Melis, M.; Pistis, M.; Perra, S.; Muntoni, A.L.; Pillolla, G.; Gessa, G.L. Endocannabinoids mediate presynaptic inhibition of glutamatergic transmission in rat ventral tegmental area dopamine neurons through activation of CB1 receptors. J. Neurosci. 2004, 24, 53-62.
71. Azad, S.C.; Monory, K.; Marsicano, G.; Cravatt, B.F.; Lutz, B.; Zieglgänsberger, W.; Rammes, G. Circuitry for associative plasticity in the amygdala involves endocannabinoid signaling. J. Neurosci. 2004, 24, 9953-9961.
72. Cannon, J.T.; Prieto, G.J.; Lee, A.; Liebeskind, J.C. Evidence for opioid and non-opioid forms of stimulation-produced analgesia in the rat. Brain Res. 1982, 243, 315-321.
73. Walker, J.M.; Huang, S.M.; Strangman, N.M.; Tsou, K.; Sañudo-Peña, M.C. Pain modulation by release of the endogenous cannabinoid anandamide. Proc. Natl. Acad. Sci. USA 1999, 96, 12198-12203.
74. Hohmann, A.G.; Suplita, R.L.; Bolton, N.M.; Neely, M.H.; Fegley, D.; Mangieri, R.; Krey, J.F.; Walker, J.M.; Holmes, P.V.; Crystal, J.D.; et al. An endocannabinoid mechanism for stressinduced analgesia. Nature 2005, 435, 1108-1112.
75. Maione S, Bisogno T, de Novellis V, Palazzo E, Cristino L, Valenti M, Petrosino S, Guglielmotti V, Rossi F, Di Marzo V. Elevation of endocannabinoid levels in the ventrolateral periaqueductal grey through inhibition of fatty acid amide hydrolase affects descending nociceptive pathways via both cannabinoid receptor type 1 and transient receptor potential vanilloid type-1 receptors. J. Pharmacol. Exp. Ther. 2006, 316, 969-982.
76. Petrosino, S.; Palazzo, E.; de Novellis, V.; Bisogno, T.; Rossi, F.; Maione, S.; Di Marzo, V. Changes in spinal and supraspinal endocannabinoid levels in neuropathic rats. Neuropharmacology 2007, 52, 415-422.
77. Palazzo, E.; de Novellis, V.; Petrosino, S.; Marabese, I.; Vita, D.; Giordano, C.; Di Marzo, V.; Mangoni, G.S.; Rossi, F.; Maione, S. Neuropathic pain and the endocannabinoid system in the dorsal raphe: pharmacological treatment and interactions with the serotonergic system. Eur. J. Neurosci. 2006, 24, 2011-2020.
78. Bisogno, T.; Melck, D.; De Petrocellis, L.; Bobrov, Myu, Gretskaya, N.M.; Bezuglov, V.V.; Sitachitta, N.; Gerwick, W.H.; Di Marzo, V. Arachidonoylserotonin and other novel inhibitors of fatty acid amide hydrolase. Biochem. Biophys. Res. Commun. 1998, 248, 515-522.
79. Capasso, R.; Matias, I.; Lutz, B.; Borrelli, F.; Capasso, F.; Marsicano, G.; Mascolo, N.; Petrosino, S.; Monory, K.; Valenti, M.; Di Marzo, V.; Izzo, A.A. Fatty acid amide hydrolase controls mouse intestinal motility in vivo. Gastroenterology 2005, 129, 941-951.
80. de Lago, E.; Petrosino, S.; Valenti, M.; Morera, E.; Ortega-Gutierrez, S.; Fernandez-Ruiz, J.; Di Marzo, V. Effect of repeated systemic administration of selective inhibitors of endocannabinoid inactivation on rat brain endocannabinoid levels. Biochem. Pharmacol. 2005, 70, 446-452.
81. Suplita, R.L. 2nd, Farthing, J.N.; Gutierrez, T.; Hohmann, A.G. Inhibition of fatty-acid amide hydrolase enhances cannabinoid stress-induced analgesia: sites of action in the dorsolateral periaqueductal gray and rostral ventromedial medulla. Neuropharmacology 2005, 49, 1201-1209.
82. de Novellis, V.; Palazzo, E.; Rossi, F.; De Petrocellis, L.; Petrosino, S.; Guida, F.; Luongo, L.; Migliozzi, A.; Cristino, L.; Marabese, I.; et al. The analgesic effect of N-arachidonoyl-serotonin,a FAAH inhibitor and TRPV1 receptor antagonist, associated with changes in rostral ventromedial medulla and locus coeruleus cell activity in rats. Neuropharmacology 2008, 55, 1105-1113.